748566
Last Update Posted: 2021-03-03
Recruiting has ended
All Genders accepted | 18 Years-65 Years |
172 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.
The trial was terminated prematurely on May 24, 2012, due to changes in organizational strategy and resources. The decision to terminate the trial was not based on any safety or efficacy concerns.
Eligibility
Relevant conditions:
Schizophrenia and Disorders With Psychotic Features
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov